SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer
Guy A. Van Hazel, Volker Heinemann, Navesh K. Sharma, Michael P.N. Findlay, Jens Ricke, Marc Peeters, David Perez, Bridget A. Robinson, Andrew H. Strickland, Tom Ferguson, Javier Rodríguez, Hendrik Kröning, Ido Wolf, Vinod Ganju, Euan Walpole, Eveline Boucher, Thomas Tichler, Einat Shacham-Shmueli, Alex Powell, Paul EliadisRichard Isaacs, David Price, Fred Moeslein, Julien Taieb, Geoff Bower, Val Gebski, Mark Van Buskirk, David N. Cade, Kenneth Thurston, Peter Gibbs
Dive into the research topics of 'SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer'. Together they form a unique fingerprint.